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DIVALENT ION METABOLISM AND OSTEODYSTROPHY IN
CHRONIC RENAL FAILURE¶
The widespread use of clhronic dialysis and renal homotransplantation,
while prolonging the lives of patients with chronic renal failure, have con-
comitantly resulted in the appearance of severe disorders of calcium and
phosphorus metabolism and disabling renal osteodystrophy (retardation of
growth and dwarfism, osteitis fibrosa, rickets or osteomalacia and, at times,
osteosclerosis). Furthermore, it is apparent that the usual conservative
measures, i.e., giving high doses of calcium, correcting acidosis with alkali,
restricting phosphates, and giving phosphate-binding antacids orally, fre-
quently fail to correct hypocalcemia and osteodystrophy or to reduce
symptoms. Some of these measures, including chronic dialysis, may actually
worsen abnormalities in osseous structure and metabolism as well as con-
tribute to deposition of calcium salts in the soft tissue. Thus, abnormalities
in calcium and phosphorus metabolism present a major obstacle to the
rehabilitation of the patient with chronic renal failure. Stanbury and Lumb1
have stressed the need for interpreting the biochemical abnormalities in the
plasma in relation to the osseous changes.
DISCUSSION OF CHRONIC RENAL FAILURE
The present report is a revised and expanded formulation (Fig. 1) of
divalent ion metabolism and osseous lesions in chronic renal failure.2 From
the available data, a unified approach to these disorders is presented. The
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formulation and discussion are based on the following generally accepted
concepts:
1.) The secretion of parathyroid hormone (PTH) is stimulated by a
decrease in the free calcium ion (Ca++)* concentration of the blood per-
fusing the parathyroid glands, and there is no conclusive evidence that
decreased amounts of magnesium in the plasma or increased concentration
of inorganic phosphate per se alters hormone secretion.'
2.) Parathyroid hormone regulates the level of Ca++ in body fluids by
enhancing the liberation of skeletal calcium, increasing the renal clearance
of PO4-, decreasing the renal clearance of calcium,' and increasing the
intestinal absorption of calcium.
3.) For any given level of parathyroid gland activity or the metabolic
state of the individual, an increase in the concentration of PO4= in the
extracellular fluid (ECF) causes a decrease in the concentration of
Ca++.'-a-' This is primarily due to a change in the skeletal-ECF equilibrium
that results in a net movement of calcium into the bones and the establish-
ment of a new steady state with a higher serum PO4. and lower Ca++.
4.) Vitamin D deficiency or resistance to this vitamin causes a defect in
the intestinal absorption of calcium in response to need, defective mineral-
ization of cartilage and the organic matrix of bone, leading to rickets
and/or osteomalacia, and impaired action of parathyroid hormone on the
skeleton.' Under these circumstances a greater-than-normal amount of
parathyroid hormone is necessary to maintain the Ca++ concentration
of body fluids and may lead to secondary hyperplasia of the parathyroid
glands. There is no evidence that the vitamin D-resistant or deficient state
alters the renal response to PTH.
5.) Hyperplasia of the parathyroid glands with increased secretion of
PTH occurs in chronic renal failure."
Vitamin D resistance (Fig. 1, A)
At some stage during the course of chronic renal failure a moderate-to-
severe resistance to the action of vitamin D on the skeleton and GI tract
develops." -9' . There is evidence to suggest that these metabolic abnor-
malities may appear long before there is serious azotemia and at times
when renal failure is relatively mild (glomerular filtration rate [GFR]
* Throughout this presentation, Ca++ will be used to indicate free calcium ion, and
calcium will be used to indicate total calcium, i.e., the sum of all fractions, complexed
and noncomplexed, in a given biologic fluid. Ca++ is measured in our laboratory by
a micro-modification of the murexide method of Ettori and Scoggan (Clin. Chim.
Acta, 1961, 6, 861).
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FIG. 1. Diagrammatic formulation of divalent ion metabolism and osteodystrophy in
chronic renal failure. The diagram has been divided in five sections: A.) Vitamin D
resistance and its consequences; B.) Reduced renal clearance of PO, through
decrease in Ca++ concentration in plasma or E.C.F.; C.) Hyperplasia and hypertrophy
of the parathyroid glands through increased renal clearance of P04; D.) The effect
of secondary hyperparathyroidism on the skeleton and its consequences; E.) Renal
excretion and clearance of calcium. The most dense arrows represent the major
contribution, or variable of primary importance; the less dense of secondary
importance; the dotted arrow of possible or questionable contribution.
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60-70% of normal)."' It appears to be independent of the type of chronic
renal disease.*
The observation that patients with chronic renal failure are resistant to
vitamin D was first emphasized by Liu and Chu in 1943.9 They found that
very large doses (greater than the equivalent of 100,000 U/day) were
frequently needed to correct the hypocalcemia, and a bone lesion indis-
tinguishable from rickets or osteomalacia. They concluded that the meta-
bolic and osseous abnormalities were not due to vitamin D deficiency
per se, but represented "an interference with the action of the vitamin
conditioned by renal insufficiency."9 Yendt, Connor, and Howarde demon-
strated that plasma from uremic patients interfered with the in vitro calcifi-
cation of rachitic cartilage whereas normal plasma did not. This suggests
the possibility that a humoral factor may be responsible, or at least con-
tribute to the vitamin D resistant state.** Dent, et al." and Stanbury, et al.'8
have also amply demonstrated this resistance, although its exact cause is
unknown. It could result from a circulating or tissue inhibitor of vitamin D
or an alteration in vitamin D metabolism (enhanced destruction or inacti-
vation). Stanbury and Lumb found that defective absorption of calcium
from the gastrointestinal (GI) tract persists until extremely high levels
of vitamin are attained in the plasma.' Since their studies,"8"' we have
treated the resistant hypocalcemia and osteodystrophy of chronic renal
failure with vitamin D and confirmed their observation that large doses,
usually in excess of 50,000 U and at times as high as 200,000 to 300,000
U/day, are necessary. It has not been conclusively demonstrated that
there is a good correlation between the degree of renal failure and the
amount of resistance to the vitamin D effect.
Once this resistant state has developed, (Fig. 1, A) it results in defective
reabsorption of calcium and, secondarily, PO4-- from the GI tract in
response to need,""89'1' and as impaired response of the skeleton to vitamin
* In the present review we are not including for discussion primary disorders of
tubular dysfunction, such as congenital renal tubular acidosis, Fanconi's Syndrome,
cystinuria, etc., which may be associated with phosphate "wasting," vitamin D
resistance, and osteomalacia. The abnormalities are the consequence of the intrinsic
renal tubular disorder rather than the presence of renal failure and azotemia. It is
reasonable to conclude, however, that if renal failure does develop in these tubular
syndromes, the metabolic abnormality of chronic renal failure will be superimposed
upon the basic consequences of the tubular defect.
** Pyrophosphates (P205) are present in microgram and milligram quantities,
respectively, in plasma and urine of normal subjects. These compounds markedly
increase the solubility of calcium phosphate salts and through this mechanism they
may interfere with the calcification of tissues at normal concentration of these salts.""8
It is possible that pyrophosphates may be present in increased amounts in the plasma
of uremic patients. Their presence would interfere with in vitro calcification of rachitic
cartilage.
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D per se and, as a consequence, to PTH.1"0"9 From empirical observations
and the experimental studies, one can conclude that these processes need
not be impaired in an "all-or-none" manner. There may be striking differ-
ences in the extent of defects among patients with comparable degrees and
duration of azotemia.' 8, 9, 11 and unpublished observations
While large doses of vitamin D are necessary to effect the optimum
absorption of calcium in these patients, the deficiency can be compensated
for in some patients by a very large intake of calcium, usually in excess of
3 gm/day. We have noted this in patients ingesting 10 to 20 grams of
calcium carbonate per day, as have Clarkson, McDonald, and deWardener.2'
However, when calcium ingestion is diminished, as it often is in patients
with chronic renal failure, and the gastrointestinal absorptive defect is
significant, the losses of calcium in the feces may cause definite calcium
deficiency. The latter may be an important factor in the bone' atrophy
(osteoporosis) that at times is a significant component of renal osteo-
dystrophy. There is convincing evidence that calcium deficiency per se
causes osteoporosis2' rather than osteomalacia or osteitis fibrosis. The
failure of a normal vitamin D effect on the skeleton must, in time, result in
rickets (in the young) or osteomalacia, and impair the skeletal action of
PTH necessary to maintain the Ca++ concentration in extracellular fluid.10
Stanbury and Lumb1 report that the hypocalcemia of renal failure,
particularly when the major osseous lesion is osteomalacia, is unresponsive
to doses of Lilly parathyroid extract of 800 U/day. Evansone demon-
strated that the i.v. administration of 1-USP U/kilo/hour over a 10-hour
period had (change < 0.7 mg. per 100 ml.) no effect on serum calcium
in chronic renal failure if the initial level was below 7.5 mg. per 100 ml.
Those with serum calcium above this level responded to the PTH infusion
with increases of 1 to 2.5 mg. per 100 ml. The unresponsive patients had
the lowest initial calcium levels. This failure of response was not due to
the already high circulating levels of PTH, for Evanson19 found that
patients with primary hyperparathyroidism (high endogenous hormone
levels) increased their serum calcium further during the PTH infusion.
Also, Berson and Yalow'5 found no correlation between the serum calcium
and the amount of the PTH (radio-immunoassay) in the plasma of chronic
renal failure patients.
Serumt calcium and phosphate (PO4-) (Fig. 1, B)
For an introduction to this section please refer to concept No. 3 above.
Phosphate: While the amount of renal failure basically is responsible for
the elevated PO4- concentration, one must delineate a number of other
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important factors contributing to the hyperphosphatemia for any given
degree of renal impairment:
1.) The phosphorus content of the diet and the amount absorbed from
the GI tract. Progressive chronic renal failure frequently is associated
RELATION of SERUM INORGANIC PHOSPHATE and TRP to GFR
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FIG. 2. The relationship between the degree of renal failure (stable creatinine
clearance) and the serum PO4 and the per cent of tubular reabsorption of P0OE.
Each point represents a different patient. The hypo- and hyperparathyroid patients
were included because of simultaneous renal impairment.
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with chronic phosphate depletion as manifested by a low 24-hour excretion
of P04--. This is probably due to poor intake, impaired absorption, and,
questionably, the deposition of P4O-in soft tissues. Hyperphosphatemia
is not usually observed before the stable GFR decreases to 25-30% of
normal. This has been ascribed to the progressive decrease in tubular
reabsorption of PO4- in the remaining nephrons, or a rise in P04--/
TAmE 1. INFLUENCE OF CALCIUM INTAKE ON CALCIUM AND PHOSPHORUS
BALANCES AND SERUM CALCIUM AND INORGANIC PHOSPHORUS
Period Body Calcium Phosphorus Serum
Case no. weight Intake Intake Balance Intake Balance Ca P
Low calcium intake mg./ mg./
kg. mg. mg./kg. mg. mg. mg. 100 ml. 100 ml.
1 1- 2 10 96 9.6 -18 358 -5 845 4.06
2 1- 2 25 161 6.4 -87 554 -26 6.06 6.25
3 47-48 38 415 10.9 -25 962 242 4.74 7.60
4 1- 4 40 271 6.8 -52 618 11 8.04 4.95
5 1- 3 25 186 7.4 -72 479 49 7.84 4.07
Normal* 56 471 8.4 63 1258 96
High calcium intake
1 3 10 796 79.6 321 358 13 8.03 3.26
2 6- 7 25 1207 48.3 63 675 -56 5.54 5.96
3 49-52 38 1915 50.4 346 962 146 6.14 4.90
4 20-21 40 1451 36.3 136 678 113 8.14 4.02
5 4- 6 25 1353 54.1 96 515 53 9.11 3.26
Normal* 56 1205 21.5 211 760 3
* Data from 12 normal Chinese in whom the average serum calcium was
10.07 ± 0.037 mg. %, and inorganic phosphorus 3.99 + 0.033 mg. % without
significant variations in relation to the different levels of calcium and phosphorus
intake. (From Liu and Chu.)"
creatinin clearance ratio, as renal failure advances. However, we have
noted that this ratio does not always increase in this manner and that
PO4m concentration may remain normal despite the severe renal failure
(Fig. 2), an indication of the low 24-hour excretion of PO4--.
2.) The degree and acuteness of lean tissue breakdown, i.e., surgical or
medical trauma, acute starvation, and glucocorticoid or tetracycline admin-
istration may all cause breakdown of lean tissue. The intracellular organic
phosphates liberated will be metabolized to PO4--, and because of the
severe renal failure the PO4m- concentration in the blood will rise until
formation and excretion are again equal.
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3.) The calcium content of the diet. Liu and Chu9 observed that when
calcium intake was increased by 700 to 1,500 mg. per day, a significant
decrease in the PO4- concentration in the plasma occurred in each patient.
This was usually, but not always accompanied by a rise in plasma calcium
(Table 1). This fall in P04= was not due to an increased loss of phosphate
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FIG. 3. The immediate biochemical effects of subtotal parathyroidectomy in azotemic
hyperparathyroidism. In case 7 (on left), calcium gluconate was infused continu-
ously to control tetany and this procedure raised the low serum calcium. In case 3
(on right), blood samples were taken at least five hours after previous injection of
calcium gluconate. (From Stanbury and Lumb.)'
in the stool (or a more negative P04-- balance) for in every case a more
positive (or less negative) balance was observed. We have also noted this
effect of high Ca++ intake on the PO4, concentration, as have Clarkson,
McDonald, and de Wardner.' The P04m must be re-deposited in the
skeleton and/or soft tissues. Also, it is possible that if the Ca++ concen-
tration is increased by the high Ca++ intake, the hypersecretion of the
parathyroid glands may be inhibited to some extent which, as you will
note next, may contribute to the decrease in P04-- concentration.
4.) How much of an increase in parathyroid secretion occurs and the
response of the skeleton to this rise probably is an important determining
a
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factor in the degree of PO4-- concentration in severe chronic renal failure.
It is apparent that if the severely damaged kidney is unable to respond
with a significant augmentation of PO4-- excretion and clearance as en-
hatnced bone reabsorption (osteitis fibrosa) liberates Ca++ and P04~-
3 - - - - -~~ - A L.L...I I I .. I 1- 3 4-MAY 1 1 10 19 20 222 2 3 4 S * C **o 10 12 13 14lS1I II It tat13 14 15 10
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FIG. 4. Effects of high phosphorus intake on calcium and phosphorus metabolism
and serum calcium and phosphate. (From Liu and Chu.)'
from the skeleton, then plasma P04= will rise to a new height. It has
been characteristic of almost every reported case of total, or almost total,
parathyroidectomy in severe chronic renal failure, that as temporary or
peirmanent hypoparathyroidism developed serum calcium and P04= fell
significantly and the latter remained at the lower level for weeks to
mronths.182' Two examples are illustrated in Figure 3. Despite the
Cl PO4=- decline in the PO.,EE clearance ratio _C1 creat as the effect of PTH
(Cl creat.)
onl the residual nephrons was removed, serum PO4- fell. Stanbury and
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FIG. 5. Metabolic balances and the effect of calciferol in azotemic osteomalacia.
Feces shown in white; urine in black. Note the rise in serum phosphorous and
the failure of serum calcium to increase despite the strongly positive calcium balance.
(From Stanbury and Lumb.)8
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Lumb' have also demonstrated that in a large number of patients with
severe chronic renal failure, with predominant bone lesions of osteitis
fibrosa or severe secondary hyperparathyroidism, not only was the plasnma
calcium higher than in those cases without severe secondary hyperpara-
thyroidism but the plasma PO4- was also higher for the same degree of
azotemia. Finally, MI. Parfitt at the University of Queensland, Australia
(personal communication), has noted that when chronic renal failure
patients with marked secondary hyperparathyroidism are dialyzed against
the usual PO4--free dialysis solution, their plasma PO,- decreases much
6.0 y = 5.12-0.074x
=" * * * ~~~~~~~r = -0.402
| _ .S * * * p~~~~~p= 0.005
w4.5
E 3.0
N-
00
0 3 6 9 12 15
DIFFUSIBLE P mg/100 ml SERUM H20
FIG. 7. The relationship between the Ca++ concentration and diffusible phosphorus in
plasma of anl unselected group of patients with chronic renal failure.
less than in chronic renal failure patients without this evidence of secondary
hyperparathyroidism. We have also observed this phenomenon in our
patients undergoing chronic dialysis. Therefore, although space did not
permit, an arrow could have been drawn on Figure 1 from "if skeleton
can respond to the increased circulating PTH" to "rise in PQ4-- in body
fluids." We have emphasized the previous factors (Nos. 1-4) because of the
tendency, at least in the American literature, to place major emphasis
on the renal failure per se as determining the concentration of PO4-- in
the plasma.
Hypocalcei,nia: We have found that under stable steady state conditions
in chronic renal failure an increase in serum PO4-- by oral or i.v. admin-
istration always causes a decrease in serum Ca++ concentration. Liu and
Chu demonstrated this conclusively in their studies.' Figure 4, taken from
their paper, demonstrates that increasing phosphorus intake from approxi-
12
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mately 500 mg. to 1,000 mg/day caused a definite increase in serum
PO4= and a fall in serum calcium concentration. A significant metabolic
response to vitamin D, with a marked increase in the intestinal absorption
of calcium and PO4:-, may fail to cause a significant rise in the concen-
tration of serum calcium if the enhanced absorption of P04- causes
greater hyperphosphatemia. This is clearly illustrated in Figure 5. Stanbury
has questioned the inverse relationship because he found no correlation
between the total plasma calcium and the P04- concentration in a large
population of unselected uremic subjects (Fig. 6). However, when Ca++
concentration is plotted against diffusible PO4= in unselected uremic
patients (Fig. 7), a significant inverse correlation is demonstrated; but it
must be stressed that because of the significant rise in the complexed
fraction of the diffusible calcium in chronic renal failure (Fig. 8),27 the
amount of calcium in plasma may not reflect accurately what is happening
to the concentration of Ca++ ion even when plasma protein concentration
and therefore protein-bound calcium appears to be normal.*
The exact chemical nature of the organic and inorganic anions, with
the exception of S04 and PO.-- forming the diffusible complexes with
calcium in chronic renal failure, is unknown, but the complexed fraction
may reach 25 to 30%o of the total serum calcium; normally the complexed
diffusible fraction represents 7 to 10%o (Fig. 8).'2 It has been our
experience and that of others (M. Parfitt, Univ. of Queensland, Australia,
personal communication), that the inverse relationship between total
calcium and inorganic P04- in the plasma is much more apparent when
azotemia follows acute renal failure. This suggests that when time does
not permit the type of metabolic adjustments observed in chronic renal
failure, the inverse relationship between Ca++ and P04-- will be more
apparent. However, it should be noted that in our diagrammatic scheme
(Fig. 1, B) the effect of a rise in PO4- on the Ca++ concentration is
represented by an arrow of intermediate thickness, indicating that this
relationship is a significant but probably not the most important cause of
the reduced Ca++ concentration in chronic renal failure. In fact, we have
on occasion noted that the P04- concentration can be reduced from hyper-
phosphatemic levels to low normal by restricting phosphorus and giving
aluminum hydroxide jel with minimal, if any, improvement in the hypo-
calcemia. An example is shown in Table 2. This emphasizes the importance
* Occasionally mild hypercalcemia has been observed in severe chronic renal failure.
It is apparent that before one can conclude that a true hypercalcemic state (a rise in
free calcium ion concentratior (Ca++) above normal exists, an analysis of Ca++ must
be made.
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of other factors in the pathogenesis of hypocalcemia in chronic renal failure
(Fig. 1, B).
As renal failure progresses, there is a significant decrease in the total
serum calcium and, more important, the Ca++ concentration (Figs. 8, 9).
It is apparent from the above discussion that because of the elevation of
the complexed diffusible fraction, the total plasma calcium measured in the
uremic patient underestimates the magnitude of the "true" hypocalcemia.
TABLE 2. SUSTAINED HYPOCALCEMIA DESPITE MARKED DECREASE
IN PO-j CONCENTRATION*
Total serum calcium POA- Creatinine
mg/100 ml. mg/100 ml. mg/100 ml.
1/22 5.9 9.0 12.3
1/23 6.4 9.0
High calcium (3 gr./day) intake combined with Al(OH)8
ingestion (4 oz/day) over 16 day period.
2/2 7.6
2/5 7.0 2.0 10.0
2/7 6.6 2.9
2/8 6.0 2.9
* Female patient age 45 with chronic atrophic pyelonephritis.
It is frequently difficult in any given patient to explain adequately the
presence, absence, or magnitude of hypocalcemia. The authors feel that
the most important factors responsible for true hypocalcemia are the degree
of elevation of the P04= concentration for any given "metabolic setting"
of the patient and, more important, the impaired responsiveness of the
skeleton to the high level of circulating PTH, a consequence primarily
of resistance to vitamin D (Fig. 1, A & B). If osteitis fibrosa is the
predominant bone lesion in any given patient with chronic renal failure,
and this can be accepted as indicating skeletal responqiveness to the excess
circulating PTH despite vitamin D resistance, then the degree of hypo-
calcemia is inversely proportional to the responsiveness of the skeleton to
PTH.' It is also possible that the vitamin D resistant state, independent of
its role in PTH responsiveness, may contribute to the skeletal defect
responsible for the hypocalcemia (Fig. 1, A). Finally, the defect in absorp-
tion of calcium from the GI tract with the development of true calcium
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deficiency may also contribute to the amount of hypocalcemia for any
given "metabolic setting" of the patient (Fig. 1, A & B).
Parathyrcid structure and function
There is no doubt that the progressive hyperplasia and hypertrophy of
the parathyroid glands in chronic renal failure is due to the prolonged
hypocalcemia.' The increased mass may at times reach enormous pro-
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FIG. 9. The Ca++ concentration in the serum of an unselected group if stable
chronic renal failure patients as compared to 13 normal patients.
portions, i.e., 10 to 50 timiies normal size,2
14,2i
4 2, 2 and it is probable that
the rate of hormone secretion increases pari passu2i"4 The authors are
unaware of any reported measurements of hormone secretion in the sec-
ondary hyperparathyroidism of chronic renal failure. However, Berson
and Yalow,18 utilizing a radio-immunoassay for the measurement of PTH
in human plasma, found that concentrations of PTH in plasma of patients
with chronic uremia were frequently much higher than those in many
patients with proven parathyroid adenoma (Fig. 10). The concentratioll
correlated better with the duration and degree of azotemia than with the
severity of hypercalcemia. Bethune, et al.,' utilizing a procedure for the
quantitative extraction of PTH excreted in the urine, has found rates of
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hormone excretion comparable to those in severe primary hyperpara-
thyroidism (personal communication). It will be noted in Figure 1 that
a dotted arrow connects the original reduced renal mass and GFR with
the increased circulating level of PTH. Recent data suggests that the
kidney may be important in the inactivation of PTH,U" and in preliminary
TABLE 3. PARATHYROID EXTRACT INACTIVATION IN VITRO*
No. of Mean plasma cakium
Samnple rats (mg. per 100 ml.)
1) Sham operated 6 10.5
2) Cautery parathyroidectomized
previous day 16 7.1
3) PTX + 10 U E. Lilly PTE 12 7.5
4) PTX + 25 U E. Lilly PTE 8 8.5
5) PTX + 40 U E. Lilly PTE 24 10.0
Incubation of 40 U of PTE with the following in Tyrode Ringer's (T-R) Type
Solution at 37, then the T-R Solution assayed for residual PTE.
6) T-R+40U 4 11.0
7) Serum + T.R. + 40 U 8 10.4
8) Liver slice + 40 U 8 8.5
9) Kidney slice + 40U 12 9.1
10) Kidney homogenate + 40 U 12 7.2
11) Heated kidney slice + 40 U 4 10.2
12) Heated kidney homogenate + 40 U 8 10.1
13) Liver homogenate + 40 U 4 9.5
14) Heated liver homogenate + 40 U 4 11.2
15) Heart homogenate + 40 U 4 9.6
16) Heparin 4 9.4
* Standards and unknown solutions assayed in the rat parathyroidectomized 24 hours
prior to injection; all assay animals were sacrificed 6 hours after injection of the
standard and unknown solutions.
experiments (Table 3) we have confirmed these findings.' Furthermore,
if a significant proportion of the secreted PTH is excreted in the urine in
an active form, one would expect that as renal mass decreased, clearance
of hormone would also decrease. Therefore, the less the excretion and
inactivation of PTH for any given rate of secretion the higher would be
the steady state circulating level.
If the skeleton is responsive to the latter, the Ca++ concentration of
the blood will return toward normal and this concentration, through nega-
tive "feed back," should inhibit further excess secretion of hormone from
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the glands. Unfortunately, the constellation of metabolic events that caused
the original sustained decrease in Ca++ concentration (Fig. 1, A & B),
continues to maintain some degree of hypocalcemia (reduced Ca++)
despite the hypersecretion, and the parathyroid glands continue to grow.
The increased mass of functioning parathyroid tissue may well create a
vicious cycle in which it requires a greater than normal Ca++ concen-
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FIG. 10. The plasma concentration of PTH normal subjects and patients with
parathyroid adenoma, bronchiogenic carcinoma with hypercalcemia and chronic renal
failure, as determined by radioimmunoassay. The results are expressed in relative terms,
utilizing dilutions of a standard plasma from case of hyperparathyroidism. (From
Berson and Yalow.)a
tration to shut off hormone secretion or at least to prevent hypersecretion.1'
The large mass of parathyroid tissue becomes relatively autonomous with-
out the development of an actual adenomatous change in one or more of
the hyperplastic glands. Recently Gittes and Radde' have carried out
elegant experiments which may be considered the experimental counter-
part of this situation. They transplanted 20-80 normal rat parathyroid
glands to the thigh muscles of normal recipient rats. This caused a sus-
tained hypercalcemia for at least 25 days, or experimental hyperpara-
thyroidism in the recipient animal. The authors concluded that the mass of
normal parathyroid tissue was so great that the sensitive "feed back"
inhibition of parathyroid secretion that normally follows a minimal rise in
18
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Ca++ concentration was unable to shut off hormone secretion and resulted
in sustained hypercalcemia. These experiments suggest that the greater
the degree of over-all hyperplasia of the parathyroid glands in chronic
renal failure the more relatively "autonomous" they will become, i.e., they
will continue to secrete excessive amounts of PTH even though the plasma
Ca++ is returned to, or even above, normal. These levels of serum Ca++
seem to be produced by the skeletal response to the hormone, or by
exogenous calcium loads, and/or effective doses of vitamin D.* However,
the magnitude of this "autonomous" function probably varies greatly from
patient to patient, being primarily dependent on the degree of hyperplasia
of the parathyroid glands.
The suppressibility of the parathyroid glands, as measured by the
reduction in the PO4-/creatinine clearance ratio during and after a calcium
infusion, may vary from relatively normal to non-suppressible. Berson
and Yalow' infused calcium into two uremic patients and noted a decrease
of 75 and 80%'o, respectively, in the concentration of PTH in their plasma
within one hour. Impaired or absent suppressibility in a given patient with
chronic renal failure may indicate that the patient is prone to develop
"autonomous, secondary hyperparathyroidism" (see Fig. 1, C) after trans-
plantation or to show increasing manifestations of secondary hyperparathy-
roidism and metastatic calcification during a chronic dialysis program.
We have found that when some patients with severe chronic renal failure
are ingesting large amounts of CaCO3, i.e., 20 grams/day with or without
vitamin D, they may rapidly develop significant hypercalcemia, which
usually disappears within a few days of stopping the high calcium intake.
In these patients hypercalcemia secondary to "excess" vitamin D may
also disappear rapidly after stopping the vitamin. These observations
suggest that the homeostatic inhibition of parathyroid secretion does not
occur in a normal manner in some chronic renal failure patients as their
hypocalcemia is corrected (Fig. 1, C).
We stated earlier that a rise in plasma PO4m-- for any given "metabolic
setting" would cause a decrease in Ca++ concentration. Conversely, a
significant reduction in PO4, concentration should contribute to a rise in
Ca++. In normal subjects, marked hypophosphatemia due to dietary P04-
restriction and aluminum hydroxide (AIOH3) ingestion does not cause
* It could be postulated that the secretion of the calcium lowering hormone of the
thyroid (thyrocalcitonin) is defective in chronic renal failure; however, until a physi-
ologic role for this hormone can be demonstrated in humans, we prefer to conclude
that abnormal increments in serum calcium in chronic renal failure are due to the
massive hyperplasia of the parathyroid glands in association with a probably decreased
inactivation and excretion of PTH.
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hypercalcemia because the normal regulatory mechanisms for controlling
serum calcium are intact. However, in primary hyperparathyroidism, when
this dietary approach causes further hypophosphatemia, a significant in-
crease in the degree of hypercalcemia almost always occurs. Recently,
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FIG. 11. The effect of chronic hemodialysis, aluminium hydroxide gel (Aludrox),
parathyroidectomy, and subsequent calciferol therapy on the serum calcium and
phosphorus in a patient with severe secondary hyperparathyroidism. The concentrations
represent those found just prior to a given dialysis. When the serum calcemia was
at its highest, the immediate post-dialysis serum phosphorus was 3.0 mg. per 100 ml.
The phosphorus concentration in post-dialysis serum prior to the Aludrox ranged be-
tween 5 and 6 mg. per 100 ml.
while visiting Auckland Hospital in Auckland, New Zealand, the senior
author was shown a case of chronic renal failure with severe secondary
hyperparathyroidism, osteitis fibrosa, and metastatic calcification where
the patient gradually developed mild hypercalcemia after many months of
hemodialysis. Because of continued hyperphosphatemia the patient was
placed on Al(OH)3 therapy for two months. During this period frank
hypercalcemia (14.5 mg. per 100 ml.) developed as P04-- fell to low-
normal (Fig. 11). Subsequent parathyroid surgery demonstrated four
20
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large diffusely hyperplastic but not adenomatous glands.* Recently, a
patient in our chronic dialysis program developed increasingly severe
nietastatic vascular calcification. This was so extreme in her digital vessels
that necrotic changes in the tips of her fingers and toes were observed.
Serum calcium was near, but always slightly below, normal and her serum
PO4- between dialyses averaged 8 to 12 mg. per 100 ml. X-rays of her
skeleton showed typical osteitis fibrosa. Subsequent to a most successful
renal transplantation (post-operative creatinine clearance 80-100 cc/min.),
she developed frank hyperparathyroidism with hypercalcemia, hypophos-
phatemia and a very high PO4-/creatinine clearance ratio (50%). The
vascular calcification and the digital ischemic changes became much more
severe. Prior to p)arathyroid surgery, PO4-- clearance did not decrease
during or after a calcium infusion that increased serum calcium to 14 mg.
per 100 ml. At surgery 3-3/4 diffusely hyperplastic parathyroid glands,
each 2-3 cm. in length, were removed. The cure of her hyperparathyroidism
has resulted in significant improvement in her digital circulation and
healing of the ischemic ulcers. We cite this and the previous examples as
cases of "autonomously" functioning hyperplastic parathyroid glands.
Comparable non-adenomatous glands have been removed in the treatment
of severe "autonomous" secondary hyperparathyroidism developing during
chronic hemodialysis and after renal transplantation." s3 Each of the
patients who developed a picture of primary hyperparathyroidism after
renal transplantation had normal-to-high-normal serum calcium and
markedly elevated PO4- prior to surgery.
Renal clearance of P04-
In Fig. 1, C we have indicated that the sustained rise in circulating
parathyroid hormone causes an increase in the renal clearance of P04--
within the limits imtposed by the degree of renal failure. Although the
U. V. of P i i r e.--e q s
absolute clearance of - - is obviously reduced, i.e., requires a
higher plasma PO4,- to excrete the normal daily phosphate load, the
PO4--/GFR (creatinine or inulin) clearance ratio in most instances
increases as renal failure progresses, at times exceeding 100% of the
calculated filtered PO4:- (Fig. 12). The available data strongly sug-
gest that the two most important factors contributing to this high clearance
* The senior author is deeply grateful to Dr. Peter Doak and the medical staff of
Auckland Hospital for presenting to him their excellent metabolic studies on this
patient.
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FIG. 12. The renal clearance of diffusible phosphate as renal failure progresses. Each
point represents a different patient.
ratio are: 1.) secondary hyperparathyroidism. There is no evidence that
the vitamin D resistant state of chronic renal failure interferes with the
action of PTH on the nephron. 2.) The increased filtered load of P04-
per nephron, which is secondary to the hyperphosphatemia, and in certain
renal diseases such as chronic pyelonephritis, an increased GFR per
residual nephron. Others have suggested that this increasing ratio as renal
failure progresses is the main factor preventing the rise in plasma PO4--
until less than 25 o of normal renal function remains.' Earlier in discussion
22
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we stressed the role of non-renal factors determining the plasma PO4-
concentration. In Fig. 2 it is evident that in an unselected population of
patients with chronic renal failure the PO4-/GFR clearance ratio does not
always rise as renal failure progresses despite the fact that many of these
patients have normal, or near normal plasma PO4= concentrations. There
is no doubt that the low P04- intake and absorption (fecal: urinary
P4O high) contributes to the sustained relatively low clearance ratio
despite the marked secondary hyperparathyroidism. Effective vitamin D
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FIG. 13. The relationship between the level of serum P and the daily urinary output
of phosphate (all cases). Three cases of Fanconi syndrome are plotted as a black
arrow. Cases of azotemic hyperparathyroidism are shown as a black star and an
open arrow. (From Stanbury.)8
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therapy, by enhancing absorption of Ca++ and PO4-:, can increase serum
P04-- excretion and clearance (Fig. 13). In fact, it should be stressed
that in far advanced kidney disease (less than 20%o of normal GFR) the
high P04=/GFR ratio becomes progressively less important in deter-
mining the PO- concentration in the plasma. Nothing could emphasize
this more than the prompt fall in plasma P04:, despite the simultaneous
fall in P04EE clearance in these patients (Fig. 3), that follows para-
thyroidectomy.
Skeletal responsiveness to PTH, nietastatic calcification and osteodys-
trophy. When the skeleton is capable of responding to the excess circulating
PTH, the result will not only be higher free Ca++ ion concentration, but
also higher PO4,n concentrations in the body fluids, the latter imposed by
the severe renal failure. The (Ca++) (PO4-) product will inevitably rise
to abnormal levels. Under these circumstances (Fig. 1, D), we will be
confronted with the desperate situation of the patient's increasing osteitis
fibrosa leading to a progressive shift of bone mineral to soft tissues,
resulting finally in clinically evident imietastatic calcification. XVe stress
"clinically evident" because it is most likely that there is a marked increase
in soft tissue deposition of calciuml phosphate salts long before they are
evident clinically or even seen with the usual technique of light microscopy.
The contribution of excess soft tissue deposition of calcium salts to organ
dysfunction is unknown. It is quite possible that excess calcium deposition
in renal parenchyma can contribute to further deterioration in renal func-
tion in chronic renal failure patients* (Fig. 1, D). A systemic study of the
soft tissue content of divalent ions in chronic renal failure is most needed.
It is our impression that the intolerable pruritis observed in some of the
patients in our chronic dialysis programii is due not to the uremia per se,
but to the deposition of calcium salts in dermal structures. Both the New
Zealand patient described above and a patient of ours had intolerable
pruritis which was not corrected by two hemodialyses per week. Total
parathyroidectomiiy without a basic improvement in their underlying renal
disease, caused complete relief of their pruritis within one week of surgery.
It should be clear that any procedure that contributes to a positive
* A careful review of the references to parathyroidectomy in chronic renal
failure'' 8t2}0 29 ',$5 does not suggest that cure of the severe secondary hyperpara-
thyroidism has resulted in appreciable improvement in renal function as measured by
BUN, NPN, or serum creatinine. However, it is well known that with changing
protein content of the diet, or any alteration in production of creatinine, these deter-
minations may not be an accurate reflection of glomerular filtration and of course
they give no indication of the state of tubular function. Therefore all chronic renal
failure patients undergoing parathyroidectomy should have careful pre- and post-
operative studies of renal hemodynamics and tubular dysfunction.
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FIG. 14. The frequency distribution of the levels of plasma calcium and phosphate
in the two separate groups with defective mineralization (Group A) and with
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squares.
calcium balance without simultaneously correcting the basic disorder(s) of
divalent and osseous metabolism will aggravate the metastatic calcification.
In Figure 1, D we have indicated that if the skeleton is unable to respond
in a normal manner to the high circulating levels of PTH, because of the
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vitamin D resistant state, osteomalacia rather than osteitis fibrosa will be
the predominant skeletal lesion. Under these circumstances the Ca++ con-
centration in the blood will be lower for any given elevation of PO4-;
in fact, as demonstrated by Stanbury, et al.,' and discussed above, the
P04= concentration will also be lower in this group (Fig. 14). On the
basis of bone histology (biopsy or autopsy), Stanbury and Lumb1 have
separated the chronic renal patients with osteodystrophy into those with
either predomninant osteitis fibrosa, or osteomalacia lesions, with the respec-
tive biochemical picture illustrated in Figure 1, D. However, it must be
stressed that if the skeleton in renal osteodystrophy could be studied in toto,
one would probably see a mixed picture of osteomalacia, osteitis fibrosa,
osteoporosis and even osteosclerosis.'8 "'S In any given case one or
another of these lesions may predominate. The magnitude of vitamin D
resistance and the responsiveness of the skeleton to PTH will vary greatly
from patient to patient and with time and degree of azotemia in a given
patient. A vivid example of this was recently afforded in one of our chronic
dialysis patients. This patient after many months in dialysis began to com-
plain of increasing bone pain. X-rays disclosed increasing demineralization
of her skeleton. She had a spontaneous fracture of her clavicle, with mini-
mal soft tissue calcification. She was treated with large doses of vitamin D
(more than 100,000 U/day). This caused a remarkable clearing of her
osseous pain and questionable improvement in skeletal mineralization;
however, increasing metastatic calcification, including skin, corneal, and
conjunctival deposition, and phalangeal lesions of osteitis fibrosa appeared.
Osteomalacia was improved, but secondary hyperparathyroidism became
worse. This patient has most recently been operated on with the removal
of three diffusely hyperplastic parathyroid glands 4 to 6 times larger than
normal; a fourth gland could not be located. It is of considerable interest
that skeletal pain may clear completely with vitamin D despite evidence
that osteitis fibrosa is not improving and actually getting worse. Physicians
following patients closely with various types of metabolic bone disease have
long been aware that osteomalacia is a much more painful disorder than is
osteitis fibrosa. In fact, one is often amazed at how severe the latter can be
with minimal skeletal discomfort.
Immobilization, calcium deficiency per se,2' and chronic protein depletion
are probably the main causes of the actual osteoporosis (bone atrophy)
component of renal osteodystrophy. In patients with chronic renal failure
over the age of 50 post-menopausal, idiopathic or "senile" osteoporosis
may contribute to the skeletal abnormality.
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Osteosclerosis: The most unusual skeletal appearance in renal osteo-
dystrophy is "osteosclerosis." The latter, in most cases, is more an X-ray
than a pathologic entity, being referred to as "increased bone density."
Histologically, the latter may represent an increased amount of normally
mineralized bone, a greatly increased amount of bone with less than normal
mineralization, or a normal amount of bone with greater-than-normal
mineralization.
In the studies reviewed,"'9 the first two were primarily responsible for
the description of "osteosclerosis" observed in renal osteodystrophy.
Garner and Ball40 carried out critical quantitative studies of bone mass and
bone density or the amount of mineralized (or calcified) and unmineralized
cancellous bone in a measured area, in a standard site in the iliac crest of
normal subjects and 18 with chronic renal azotemia. They found that in
most cases the osteosclerosis is due to the accumulation of unmineralized
bone (osteoid) in association with an increased total bone mass. The
mineralized bone mass is usually within normal limits but in four cases
was actually increased. Varying degrees of osteitis fibrosa and irregular
marginal erosion of the mineralized bone was evident in 15 of the cases.
Presumably, osteoid accumulates because of the increased osteoblastic
activity, and because of the resistance of osteoid to osteoclasis. In none of
the studiesg could "osteosclerosis" be correlated with any specific pattern
of change in the serum levels of calcium, PO,-, or alkaline phosphatase.
The increased osteoblastic activity may be due to the chronic effect of the
excess circulating PTH acting on a skeleton made resistant to the actions
of the hormone by the uremic state, the result being a greater degree of
osteoblastic activity for any given degree of osteoclasis.<
' Ball and Garner'
have further suggested that the occasional case of hypermineralization, or
an. increased amount of mineralized bone in renal osteodystrophy may
result from an excess production of abnormal, more readily calcifiable bone
matrix (woven) rather than the normal lamellar pattern.
The role of metabolic acidosis
While chronic acidosis can bring about a significant loss of the acid
soluble calcium (carbonates) of the skeleton,' its contribution to the histo-
logic lesions of renal osteodystrophy is extremely difficult to assess. Jaffe,
et al.' demonstrated that ingestion of large amounts of ammonium chloride
(0.4-1 gm/kg) for 11 weeks did not produce skeletal lesions in the oldest
dogs (18 months) maintained on normal calcium intake. They found that
the younger the animal (down to 3 months) and the lower the calcium
intake, the more severe was the bone pathology. Their illustrations of the
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gross characteristics of the skeleton showed extensive bone atrophy in
the most severe cases. Their description of the microscopic changes sug-
gests osteitis fibrosa of a minimal degree in the latter. No osteomalacia or
rickets was observed. Unfortunately, in none of these studies were there
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FIG. 15. Serum bicarbonate concentration and cumulative chaniges from control in
balances of acid, calcium, and phosphorus during control, ammonium chloride loading,
and recovery periods. (From Lemann, Litzow, and Lennon.)'
mneasurements of the calcium, PO4-, or acid-base status of the blood and
the parathyroid glands were not examined. The studies of Lemann, et al.'
indicate that when severe metabolic acidosis is produced for 18 days in
niormal human subjects (Fig. 15) a most profound negative calcium balance
occurs. It is apparent that losses of this magnitude would result in severe
demineralization of the skeleton if they persisted for weeks to months. It is
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impossible to know whether the varying degrees of chronic and recurrent
acidosis observed in chronic renal failure could produce the same phenome-
non once the calcium carbonate component of the skeletal mineral was lost."
Investigations of the effect of chronic metabolic or renal acidosis in the
experimental animal on the simultaneous calcium metabolism, parathyroid
function, response to vitamin D, and gross and microscopic morphology of
the skeleton are not available. We do know that chronic treatment with
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FIG. 16. The renal clearance of diffusible calcium related to the severity of relnal
failure (stable creatinine clearance). Each represents a different patient.
NaHCO,, while causing a slight improvement in negative calcium balance,47
does not cause a positive calcium balance, or correct hypocalcemia, skeletal
pain or X-ray changes.1'1'" The role of pyrophosphate (P,0,),' ' or
fluoride retention in chronic renal failure remains to be critically evalulated.
The renal excretioni of calcium and mnagnesium
Calcium: We have earlier alluded to the contribution of the changes in
PO4' excretion and clearance to the biochemical and osseous abnormalities
in chronic renal failure. In contrast, the alteration per se in the renal
handling seems of secondary importance. Almost all patients with renal
insufficiency have varying degrees of absolute hypocalciuria (a reduced
excretion for any given filtered load (Fig. 1. E). This may be observed
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despite only mild renal impairment).", unpublishedobservations While hypocalci-
uria characterizes the steady state excretion of calcium, the clearance of
diffusible (non-protein bound) calcium relative to the residual rate of
glomerular filtration or calcium clearance "per nephron" is actually greater
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than normal (Fig. 16). It can be seen that this ratio, in general, increases
as renal failure progresses. This pattern is quite similar to the renal
handling of many ions (Na+, K+, Mg++, Cl, PO4-) as functional renal
n-iass decreases in chronic renal failure. It can be reasonably well correlated
with the increased osmotic and, particularly, Na+ "load per nephron"
(Fig. 16).
It is our impression that the calcium clearance/GFR ratio in chronic
renal failure is greater in chronic pyelonephritis, or diseases with rela-
tively more severe tubular than glomerular injury, than in the primary
"glomerular" disorders, i.e., glomerulonephritis (Fig. 17). It is in the
former that we also see the greatest "salt wasting." In view of the extremely
close interrelationship between sodium and calcium excretion in normal
animals and humans,'9 it is quite possible that such. factors as increased
osmotic load and GFR per nephron that contribute to the salt wasting
in chronic renal failure,' exert a comparable effect on calcium. We are
unable to correlate the absolute hypocalciuria or the clearance. ratio with
the steady state concentration of plasma diffusible calcium or the calculated
filtered load of calcium. There is, however, a significantly positive corre-
lation with the complexed diffusible fraction of the total plasma calcium'
when clearance ratios are determined from random timed urine collections
in the stable chronic renal failure patient.
It seems most unlikely that the reduced renal mass and the reduced
filtered load of calcium per se can be a major cause of the absolute hypo-
calciuria of chronic renal failure. For that reason we have represented
this interrelationship by a broken line on the left-hand side of Figure 1.
Evidently, although Ca clearance/GFR ratio is greater than normal in
chronic renal failure (Fig. 16), the residual nephrons must be attempting
to conserve calcium within the limits'imposed by the solute and' Na+ load/
iiephron. In other words, the Ca'clearance/GFR ratio would be even higher
if the residual nephrons were not'maintaining the absolute hypocalciuria.
The question can be asked what factors'are responsible for the attempt at
renal conservation of calcium by the residual nephrons in chronic renal
failure? It is known that when the renal function is normal, PTH,' calcium
deficiency per se, vitamin D deficiency (or true primary resistance), and
high-PO4- intake (with or without increased serum PO4-) all may cause
a reduction in the renal clearance and excretion of calcium. It is presently
thought that PTH decreases the renal clearance of calcium by a direct
effect on-the nephron.7 It is not known how calcium and/or vitamin D
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deficiency or high PO4- intake* cause the kidney to conserve calcium
maximally. In part it may be due to the physiologic secondary hyperpara-
thyroidism which occurs in these states. Suffice it to say that in chronic
renal failure all of these factors probably contribute to the absolute hypo-
calciuria, as indicated in Figure 1, E. Positive calcium balance brought
about by large oral loads of calcium, or by intravenous infusions of calciun
without a basic correction of the underlying metabolic defects (Fig. 1),
will, as they increase plasma calcium, increase the clearance and excretion
of calcium in chronic renal failure patients.9' 0' unpublished observations It is of
great interest that the pattern of increase in Ca clearance/GFR ratio that
occurs in chronic renal failure patients, as their plasma calciuln is raised
by infusion of CaCl2,, is remarkably similar to that of normal subjects
receiving similar infusions while under the influence of two-hourly injec-
tions of parathyroid extract.7 It is important to note that when large doses
of vitamin D bring about a marked improvement in osseous metabolism,
strongly positive calcium balance due to enhanced absorption of calcium
from the GI tract, and a significant correction of hypocalcemia, urinary
calcium may remain very low despite an unequivocal rise in the filtered
load of calcium (Fig. 18).`` This would indicate a further reduction in
calcium clearance as the beneficial effect of the vitamin D on the skeleton
(new mineralization and bone accretion) somehow signals the kidney to
retain as much calcium as possible for osseous needs. To the authors'
knowledge there is no clear-cut evidence that vitamin D per se has a direct
effect on the renal clearance of calcium.' It is apparent from the above
discussion that the alteration in the renal handling of calcium, as nephron
destruction progresses, is secondary to the over-all derangement in divalent
ion and osseous metabolism and it does not contribute to the development
of the osteodystrophy or hypocalcemia. However, a severe reduction in
renal mass may remove a safety valve factor that contributes to the
homeostatic prevention of hypercalcemia associated with excessive calcium
ingestion and/or vitamin D intoxication. The ability of the normal kidney
to develop significant hypercalciuria without appreciable hypercalcemia is
* While there is no doubt that high PO4- intake in normal subjects almost invariably
causes a reduction in urinary calcium and positive calcium balance, probably by
shifting the equilibrium of calcium phosphate salts "back into the skeleton," it is
not known whether the hyperphosphatemia independent of high PO4M intake can
contribute to the hypocalciuria of chronic renal failure. In two patients with severe renal
failure (creatinine clearance 4 and 15 cc/min) maintained on low P04m intake and
antacids for 7-8 days so that their serum P04EE fell 2.5-3.0 mg per 100 ml., the severe
hypocalciuria (< 20 mg/24 hours) was not altered. However, it may be necessary to
restrict P04-- intake considerably longer than 7-8 days in the chronic renal failure
patient to demonstrate the hypercalciuric effect of PO4.E: depletion.
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FIG. 18. Metabolic balances and the effect of dihydrotachysterol in azotemic rickets.
Note that despite the positive calcium balance and the marked rise in serum calciuml
(and filtered load), the urinary calcium did not increase. (From Stanbury.)8
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an important mechanism for clearing excess calcium from the blood when
the buffering capacity of the skeleton is blunted by disease (i.e., osteitis
fibrosa), or when excessive bone resorption is occurring. An elegant experi-
mental example of this safety valve role of the kidney has been brought to
the senior author's attention by Dr. M. Parfitt, Dept. of Med., Univ. of
Queensland Medical School, Australia. He has confirmed that chronic
administration of thiazide diuretics can cause significant hypocalciuria in
normal subjects and patients with idiopathic hypercalciuria.' While study-
ing the effect of thiazides on the hypercalciuria that frequently accompanies
successful vitamin D treatment of hypoparathyroidism, he noted that a
patient developed frank hypercalcemia when the urinary calcium was sig-
nificantly reduced by thiazide ingestion and that the hypercalcemia promptly
disappeared when the diuretic was stopped and hypercalciuria reappeared.
He subsequently realized that this patient had mild vitamin D intoxication
and was probably on the verge of developing hypercalcemia. It is common
knowledge that patients with hypercalcemic disorders of any etiology may
develop much more severe hypercalcemia if pre-renal azotemia occurs from
salt and water depletion. Therefore in chronic renal failure the loss of the
renal safety valve may predispose, under certain circumstances, to the
more rapid development of hypercalcemia.
Magnesium: Although alterations in magnesium metabolism do not
appear to contribute to the osteodystrophy, it seems appropriate to refer
to magnesium in any discussion of divalent ion metabolism in chronic
renal failure. In our own studies we were surprised to find how rarely
hypermagnesemia was present in azotemic patients. No alterations in the
protein (non-diffusible) to non-protein bound fraction of plasma mag-
nesium was detected (Fig. 8); in fact, if the patient had been eating poorly
for a number of days it was not unusual to see mild hypomagnesemia with
the continued urinary excretion of significant anmounts of miagnesium
(Mg++ "wasting syndrome").
Investigations of magnesium and calcium clearance in patients with
chronic renal failure has demonstrated why significant elevations of plasma
magnesium are unusual. In normal subjects the clearance of diffusible
magnesium is usually 2 to 2.5 times the simultaneously measured calcium
clearance, or approximately 4-6%o filtered magnesium." As renal failure
progresses, this ratio (Mg/Ca clearance) increases (Fig. 19) and
magnesium clearance may reach 60-70% of the filtered magnesium. It is
readily apparent that despite marked reduction in renal mass the absolute
clearance of magnesium may remain very close to normal and therefore
plasma magnesium will also remain normal. This rise in Mg clearance/GFR
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ratio as renal failure progresses resembles much more closely the altered
renal handling of potassium rather than that of calcium. Therefore we see
the kidney in chronic renal failure trying to conserve calcium maximally
while rejecting magnesium. We recently had the opportunity to see a
patient with severe renal failure secondary to pyelonephritis, who entered
the hospital with bizarre CNS symptoms and a serum magnesium of
0.85 mg. per 100 ml. or approximately 11/3 of normal. His history indicated
extremely poor food intake for many weeks prior to admission. On
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FIG. 19. The renal clearance of diffusible magnesium related to the severity of renial
failure (stable creatinine clearance). Each point represents a different patient.
admission his urine was free of magnesium. As repletion occurred with
intravenous and intramuscular administration of magnesium salts, urinary
Mg rose rapidly despite continued hypomagnesemia. When his serum
magnesium had returned to normal (2.66 mg. per 100 ml.), the Mg++/
GFR clearance ratio was 0.5. It seems reasonable to conclude that his
very poor intake of magnesium, coupled with the continued renal wasting
of this ion, caused the severe magnesium depletion syndrome. Of additional
interest in this patient was the severe hypocalcemia (5.0 mg. per 100 ml.)
also present on admission. With magnesium repletion the serum calcium
rose to 8.5 mg. per 100 ml. and remained at this level without supple-
mental calcium or appreciable improvement in renal function. Heaton,
et al.5M demonstrated the magnesium deficiency in man predisposed to hypo-
calcemia. They suggest that this deficiency interferes with calcium release
from bone.
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The exact mechanisms responsible for the magnesium "wasting" of
chronic renal failure is unknown. However, Chesley, et al.> and Barker,
et al. concluded that a reabsorptive Tm (maximal rate of tubular reabsorp-
tion in mgs/min.) for magnesium does exist and that it is very close to the
normal concentration of filtered magnesium. Therefore, any slight increase
in the plasma concentration of magnesium or in the filtered load per
nephron in the chronic renal failure patient would quickly "saturate" the
reabsorptive capacity of the remaining nephrons and the additional filtered
magnesium would appear quantitatively in the urine. This concept requires
experimental confirmation. The only time we have observed significant
hypermagnesemia in chronic renal failure is when excessive amounts of
magnesium are infused or the patient ingests large quantities of an antacid
containing magnesium.' In our patients with chronic renal failure we were
unable to demonstrate any specific interrelationship between total and
diffusible plasma magnesium and calcium.
THERAPY
If the symptomatic and/or corrective therapy of the disorders of
divalent ion metabolism and osteodystrophy in cronic renal failure is to
be of reasonable value to the patient, the physician must be aware of the
general concepts discussed in the preceding paragraphs and outlined in
diagrammatic fashion in Figure 1. It will become increasingly apparent
that while correcting one biochemical abnormality in this constellation the
therapist may be seriously aggravating another. Therefore, each patient
must be critically evaluated before introducing any long-term form of
corrective therapy and re-evaluated at appropriate intervals to convince
oneself that what was previously good for the patient has not become bad.
It is almost axiomatic in the treatment of chronic renal failure that any
reversible pre-renal or post-renal components should be corrected. This
correction should be of benefit in ameliorating the sequence of events
(Fig. 1) set in motion by the reduction in renal mass and renal hemo-
dynamics. Once these reversible factors are corrected we are left with the
stable chronic azotemic patient, usually with varying degrees of hypo-
calcemia and hyperphosphatemia, with or without clinical evidence of osteo-
dystrophy. Our fundamental over-all approach should be to: 1.) return the
skeleton to normal; 2.) correct, and prevent soft tissue deposition of
calcium salts, and 3.) maintain the free Ca++ ion and P04m- concentrations
in the blood as near normal as possible. It is questionable whether mild
degrees of hypocalcemia (7-8 mg. per 100 ml.) or hyperphosphatemia (less
than 5.5 mg. per 100 ml.) per se require specific treatment unless they are
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associated with significant radiologic, pathologic (biopsy), or clinical evi-
dence of osteodystrophy. A decision as to the introduction of large-dose
vitamin D therapy must rest on the presence of evident osseous pathology
and the ease with which moderately-severe-to-severe hypocalcemia can be
corrected with more conservative measures. Hyperphosphatemia can be
corrected by rigid phosphate restriction and the administration of alkaline
earth antacids that bind PO.I-- in a non-absorbable form.' As the P04-
concentration in the plasma returns to normal, a significant rise in calcium
concentration may occur. This will be hastened by the simultaneous admin-
istration of liberal quantities of calcium salts. CaCO3 (20-30 gm/day) may
supply the calcium ion, "bind" P04- in the GI tract and correct mild
acidosis." unpublished observations
It is apparent from examination of Figure 1 and the earlier discussion,
that the correction of hypocalcemia by this conservative approach will
depend on the magnitude of the vitamin D resistant state and the skeletal
responsiveness to PTH (Fig. 1). It must be stressed that calcium "loading"
and an elevation in the free Ca++ concentration that is not accompanied
by a significant reduction in PO4-- will result in a further rise in the
already elevated (Ca++) (PO4-) product.2" unpublishedobservations This could
only lead to more soft tissue deposition of calcium salts if the fundamental
skeletal abnormality is not improved. True hypercalcemia can be caused
by high calcium ingestion per se. This would be due to defective "buffering"
capacity of the skeleton and the loss of the "safety valve" function of the
kidney. Finally, although chronic dietary PO4-- restriction and antacid
administration can cause a significant reduction in PO4= concentration
and therefore in the (Ca++) (PO4-) product and even at times correct
overt metastatic calcification if the serum P04- can be returned to normal5'8
(also, unpublished observations, and F. H. Epstein, personal communica-
tion), one must be aware that this therapy lowers plasma PO4-- by causing
phosphate depletion. The latter may already be present in a patient with
severe renal failure and the treatment would make it worse. Phosphate
depletion per se may seriously interfere with normal mineralization of the
skeleton, increase the loss of calcium from bone to ECF and soft tissues,
cause a significant negative calcium balance' and aggravate osteoporosis
and osteomalacia.
It is appropriate to mention at this time that one always hopes that any
technique that returns the Ca++ concentration of the plasma to normal
will shut off the excess secretion of PTH and prevent the undesirable
consequences of secondary hyperparathyroidism (Fig. 1, C & D). Unfortu-
nately, some degree of "autonomous" hypersecretion may continue in many
37YALE JOURNAL OF BIOLOGY AND MEDICINE
cases and under these circumstances if the skeleton can respond to PTH,
or our treatment (vitamin D or dialysis) improves its responsiveness, we
may simply aggravate osteitis fibrosa, soft tissue calcification, and pre-
dispose the patient to hypercalcemia. It may be possible to determine which
patients with chronic renal failure have "autonomously" functioning para-
thyroid glands and therefore plan the most acceptable therapeutic approach.
If after returning the plasma PO--- to a normal level with alkaline earth
gels, mild but definite hypercalcemia develops, PTH hypersecretion is
continuing. If hypercalcemia does not develop, the patient may be given a
4-6 hour infusion of 1.5 to 2.5 gin. of Ca++ ion as CaCl2 while following
serum Ca++ and PO4- and the PO4,/GFR clearance ratio at 4-hour
intervals for 24 hours. If the clearance ratio decreases 50% or more 12 to
24 hours after starting the calcium infusion, it probably indicates reason-
able suppressibility of the hypersecreting glands."' Conversely, a failure
of the PO4, clearance to fall indicates autonomously functioning para-
thyroid glands.'9 It would be ideal to measure directly the change in the
plasma concentration of PTH (radio-immunoassay), or in the renal
excretion of extractable PTH'8 during and after the standard infusion of
calcium. It should be noted that we recommend infusion of 1.5 to 2.5 gm.
of calcium ion (25-40 mg/kilo) rather than the usual gram dose utilized
when renal function is normal. It has been our experience that when renal
osteodystrophy is present the lower dose of calcium may be temporarily,
but rapidly "taken up" by the skeleton, and questionably the soft tissues,
and little or no hypercalcemia will develop to inhibit parathyroid secretion.
In those cases where vitamin D therapy seems most indicated (severe
skeletal demineralization, overt rickets or osteomalacia in association with
low plasma calcium and minimal hyperphosphatemia (Fig. 1), it may pro-
duce a remarkable amelioration of bone pain, return the calcium concen-
tration to normal and correct rickets, osteomalacia, and secondary hyper-
parathyroidism (osteitis fibrosa).1"8,9,11 Although the underlying renal dis-
ease is not corrected, the patient may be markedly rehabilitated. As shown
in Figures 6 and 14, a good metabolic response to vitamin D with enhanced
absorption of calcium and phosphorus may actually cause increasing hyper-
phosphatemia. If severe, this probably should be treated by the addition of
PO'4- binding antacids. Because of the vitamin D resistant state the patient
may require 1 to 10 mg. (40,000-400,000 units) of active sterol and we
rarely initiate treatment with less than 50,000 units.
If the vitamin D therapy is effective and as the Ca++ concentration
returns to normal, the hyperplastic, hypersecreting parathyroid glands can
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be "shut off." The entire osteodystrophy syndrome may be corrected.
Under these circumstances any calcium salts that have left the skeleton
and been deposited in soft tissues should now return to the healing hungry
bones. If, however, an optimum vitamin D response occurs in a patient
with "autonomously" functioning parathyroid glands, a new difficulty is
created. The osteomalacia component of the osteodystrophy may be cor-
rected and bone pain disappears but, because the skeleton now becomes
responsive to the excess circulating PTH (Fig. 1, A) a tendency towards
hypercalcemia appears and progressive osteitis fibrosa develops. This is
usually accompanied by increasing metastatic calcification (eyes, skin,
joints, vessels, etc.), particularly if the patient is also ingesting large
amounts of calcium and alkali or receiving them from repeated chronic
dialysis. There may be no way to correct the syndrome short of stopping
the vitamin D and allowing the pre-vitamin D state to re-develop, or by
total parathyroidectomy. The latter seems by far the most sensible. The
symptomatic improvement of the patient may be overwhelming; the osteitis
fibrosa may heal and the calcium salts deposited in a most destructive
manner in the soft tissues will return to the skeleton. High dose vitamin D
therapy, of course is continued to treat the surgical hypoparathyroidism
and prevent the redevelopment of osteomalacia or rickets.
If the skeleton of the untreated patient with severe chronic renal failure
is relatively responsive to the very high levels of circulating PTH (Fig. 1,
C), he may first appear with near-normal or normal total plasma calcium
despite severe hyperphosphatemia. Bone X-rays will frequently show
definite osteitis fibrosa, especially subperiosteal bone resorption in the
phalanges and there may or may not be evident soft tissue calcification. As
mentioned above, P04= restriction and/or vitamin D treatment in this
patient may cause frank hypercalcemia with all its adverse consequences.
Even though this patient may be in over-all negative calcium balance, if
metastatic calcification is marked, it may be necessary, at least temporarily,
to rigidly restrict calcium intake or "remove" calcium from the body by
dialysis. It is evident that the latter is only a necessary "stop gap" measure,
pending parathyroidectomy to prevent the inexorable destructive process.
Once parathyroidectomy is carried out, high-dose vitamin D therapy can
be introduced to treat the residual osteomalacia and hypoparathyroidism.
If the action of PTH on the skeleton could be blocked by medical means, it
would be possible to treat this type of patient without parathyroid surgery.
The calcium lowering hormone, thyrocalcitonin, could prove to be such a
medical treatment for it can directly antagonize the calcium mobilizing
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effect of PTH and inhibit bone resorption.' It certainly should be utilized
experimentally in this clinical setting.
Finally, what is the effect(s) of engrafting recurrent or chronic peri-
toneal or hemodialysis upon the basic metabolic disorders shown in
Figure 1? By correcting azotemia per se, it is quite possible that there may
be temporary responsiveness of the skeleton to the excess circulating PTH.
Simultaneously, in most cases, the PO4-- concentration will decrease, the
free Ca++ concentration will increase, and acidosis will be corrected. As
mentioned earlier, despite phosphate-free dialysis, correction of acidosis,
and glucose loading with peritoneal dialysis, the plasma PO4-- concentra-
tion may decrease only slightly if severe secondary hyperparathyroidism
and osteitis fibrosa are present. If the Ca++ concentration of the dialysis
bath is not significantly below that of the blood, a positive balance of
calcium (bath to patient) will occur. Because in most medical centers in
the past Ca++ concentrations in the bath have been maintained between 8
and 10 mg per 100 ml. (4-5 mEq/l), positive Ca++ balance has been the
rule. Although the skeleton needs this calcium, the soft tissues do not.
From the above, the optimal theoretical benefit from dialysis would be
achieved if Ca++, P04-- and HCO3- (blood pH) concentrations returned
to normal, and if a "temporary" increased sensitivity to vitamin D and
a normal feed back inhibition of parathyroid secretion occurred as Ca++
concentration returned to normal. Circulating PTH levels would then fall
and all hormonal and non-hormonal changes would be conducive to re-
calcification of the skeleton, new bone accretion or formation without
enhanced soft tissue deposition. Unfortunately, this ideal correction of
the metabolic defects is probably an unusual occurrence. A number of
adverse patterns of response may be seen in a chronic dialysis program.
1.) A failure to improve the vitamin D resistance or completely "shut
off" the excess PTH secretion. If under these circumstances a negative
Ca++ and POJ4- balance is achieved by appropriately low concentrations
of Ca++ and P04= in the dialysis bath, soft tissue calcification will be
prevented but the demineralization of the skeleton will worsen. Therapeu-
tically adequate doses of vitamin D may correct the osteomalacic com-
ponent but make the skeleton more responsive to the excess PTH; osteitis
fibrosa may then ensue.
2.) If the same result is achieved as in the preceding paragraph, but
the Ca++ content of the dialysis bath causes a positive balance with each
dialysis, soft tissue deposition of Ca++ salts and metastatic calcification
will occur.
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3.) Increased sensitivity to endogenous or exogenous vitamin D, but
sustained hypersecretion of PTH, mnay lead to the rapid (weeks) develop-
nment of severe osteitis fibrosa with or without metastatic calcification.
4.) Clhronic dialysis engrafted on a patient who already has overt
"autonomous" secondary hyperparathyroidism with or without metastatic
calcification, would cause increasingly severe osteitis fibrosa with more
transfer of calcium salts from bone to soft tissues. In such a patient, the
P04= concentration would tend to decrease less witlh each dialysis and
the rise in calcium ion concentration (from bone or dialvsis bath) would
b)oth cause more metastatic calcification. The latter may reach enormous pro-
portions. The whole picture could only be aggravated by simultaneous
treatment of this patient with therapeutic doses of vitamin D. Finally,
correcting metabolic acidosis or, at times, even producing mild-to-moderate
alkalosis will enhance the tendency during all of the above to metastatic
calcification, the calcium phosphate salts being more insoluble in alkaline
mnedia. Unless blood pH is being monitored, the physician may be unaware
that alkalosis is present because the HCO3- content of the post-dialysis
plasma is not greater than normal. However, chronically uremic patients
mnay have mild-to-moderate central hyperventilation.' This may not be
corrected by the dialysis. The continued low pCO2 with normal HC03-
will result in respiratory alkalosis. In recent years most chronic dialysis
centers have been aware of an increasing incidence of band kerotopathy or
corneal and conjunctival metastatic calcification in their patients. In the
experience of the senior author, one hypercalcemic disorder in which this
finding is most common is Burnett's, or the milk-alkali syndrome, or
chronic CaCO3 ingestion in peptic ulcer patients. Alkalosis is simultane-
ously present in almost all these patients.
As patients are being kept alive for longer and longer periods in chronic
dialysis programs, all combinations of the above adverse responses are
being seen with disturbing frequency. The common denominators of most
seem to be the addition of calcium phosphate salts to the soft tissues and
the probably continued secretion and/or effects of excess PTH. Avoidance
of the latter by parathyroidectomy will generally prevent or correct the
former while allowing optimum therapy with vitamin D and exogenous
calcium and phosphate salts. It is apparent that total parathyroidectomy or
a non-surgical technique (thyrocalcitonin) to block the osseous effects of
PTH will become increasingly common in chronic dialysis programs.
While a successful renal transplantation may bring about a total correc-
tion of the divalent ion abnormalities and the osteodystrophy, we and
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others"'g' have seen the development of unequivocal "autonompus" sec-
ondary hyperparathyroidism with frank hypercalcemia, hypophosphatemia,
very high phosphate clearance, hypercalciuria* and increasingly severe
metastatic calcification. The markedly hyperplastic hypersecreting para-
thyroid glands now in association with relatively normal renal function,
cause the development of this syndrome. It is our impression that this
syndrome occurs in those patients who demonstrated severe secondary
hyperparathyroidism (near normal plasma Ca++, despite elevated PO4-,
some osteitis fibrosis, with or without metastatic calcification) prior to
renal transplantation.2' This suggests that it would be of benefit before
operation to determine, as described above, whether the patient has "auton-
omously" functioning parathyroid glands.
The syndrome of post-transplantation hyperparathyroidism may appear
days, weeks, or months after surgery and we have seen at least one case in
whom a moderate syndrome disappeared spontaneously. The latter has also
been observed by McIntosh, et al.' and Herdman, et al."1 This spon-
taneous disappearance of the hyperparathyroid syndrome suggests that in
the mild cases with minimal hypercalcemia and no evidence of deteriora-
tion in renal function., it may be appropriate to withhold surgery and(
follow the patient closely. These patients would seem to be ideal candidates
for treatment with inorganic phosphate salts"2 if the latter can correct the
hypercalcemia and return the serum PO4- to normal. A theoretical objec-
tion to this form of therapy could be that spontaneous disappearance of the
hyperparathyroid state may be delayed or prevented by lowering the Ca++
concentration of the blood perfusing these "autonomously" functioning
parathyroid glands. It must be remembered that all these post-transplan-
tation cases are taking immuno-suppressive drugs and adrenal glucocorti-
coids. Consideration must be given to the contribution of this therapy to
the disordered calcium and phosphorus metabolism.
In the moderate-to-severe cases of persistent hyperparathyroidism,
parathyroidectomy must be done. In contrast to the total parathyroidectomy
suggested in the azotemic patient on chronic dialysis patients, we would
recommend sub-total removal of 3y2-3-3/4 glands. It is obviously better to
attempt to return the post-transplant patient to a euparathyroid state if
his renal function is relatively normal.
* Because almost all of these patients are on high-dose glucocorticoid and immuno-
suppressive drugs, the magnitude of their hypercalciuria is, in our experience,
considerably greater than is usually seen in primary hyperparathyroidism with the
same degree of hypercalcemia.
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